Evidence map›Paper›PMID 42098859›Full record

ArticleEpigenetics & chromatin2026

H1.3 depletion in AML cells prompts H1.2 redistribution, chromatin remodeling and cell cycle defects.

Clara Tellez-Quijorna, Lia N'Guyen, Núria Serna-Pujol, Maeva Rodies, Pau Homs-Aguadé, Julien Vernerey, Albert Jordan, Estelle Duprez

Abstract read
In one paragraph

Article in Epigenetics & chromatin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Clara Tellez-QuijornaIntegrative Molecular Biology in Hematopoiesis and Leukemia, Equipe Labellisée Ligue Contre le Cancer, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France.
Lia N'GuyenIntegrative Molecular Biology in Hematopoiesis and Leukemia, Equipe Labellisée Ligue Contre le Cancer, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France.
Núria Serna-PujolDepartment of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, 08028, Spain.
Maeva RodiesIntegrative Molecular Biology in Hematopoiesis and Leukemia, Equipe Labellisée Ligue Contre le Cancer, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France.
Pau Homs-AguadéDepartment of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, 08028, Spain.
Julien VernereyCRCM Integrative BioInformatics platform, CIBI, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France.
Albert JordanDepartment of Structural and Molecular Biology, Instituto de Biología Molecular de Barcelona (IBMB), Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, 08028, Spain.
Estelle DuprezIntegrative Molecular Biology in Hematopoiesis and Leukemia, Equipe Labellisée Ligue Contre le Cancer, CRCM, Inserm UMR1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Univ, Marseille, France. estelle.duprez@inserm.fr.

Funding

H2020 Marie Skłodowska-Curie Actions # 813091 ARCHInstitut National du Cancer PRT-K16-071Spanish Ministry of Science PID2023-146239OB-I00
6 · The paper itself

Abstract

Linker histone H1 variants play critical, yet distinct, roles in chromatin organization and gene regulation. However, their specificity in cancer cells is not well understood. Our previous studies have shown that acute myeloid leukemia (AML) patients who were H3K27me3HIST1-positive exhibited lower H1.3 expression and a favorable outcome. These results imply that the H1.3 linker histone may play an unknown role in AML progression. In this study, we investigated the function of the H1.3 variant in AML cells. Through chromatin mapping and transcriptomic analyses, we revealed that H1.3 was enriched in regions with a high GC content and colocalized with the repressive mark H3K27me3. This supports its role in chromatin compaction and transcriptional repression. Knockout of H1.3 induced specific changes in gene expression profiles and chromatin dynamics, characterized by a changed in H1.2 localization, which was redistributed from its usual chromatin regions to H1.3 regions. Consequently, we observed chromatin alterations associated with changes in gene programs affecting interferon-related signaling and cell cycle regulation. Overall, our study revealed a mechanistic connection between H1.3 variant imbalance, immune response activation, and cell cycle regulation, with implications for our understanding of epigenetic regulation in AML cells.

Indexed as

Cell CycleChromatin Assembly and DisassemblyHistonesLeukemia, Myeloid, AcuteCell Line, TumorChromatinHumansChromatinHistonesAcute myeloid leukemiaChromatin organizationHistone H1.3Linker histoneTranscriptomic

Identifiers

PMID42098859
PMCPMC13321521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.